A subset of cerebrospinal fluid proteins from a multi-analyte panel associated with brain atrophy, disease classification and prediction in Alzheimer's disease

PLoS ONE

Volumn 10, Issue 8, 2015, Pages

  Khan, Wasim ^a,b   Aguilar, Carlos ^c   Kiddle, Steven J ^a,b   Doyle, Orla ^a   Thambisetty, Madhav ^d   Muehlboeck, Sebastian ^a,b   Sattlecker, Martina ^a,b   Newhouse, Stephen ^a,b   Lovestone, Simon ^e   Dobson, Richard ^a,b   Giampietro, Vincent ^a   Westman, Eric ^a,c   Simmons, Andrew ^a,b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b King s College London   (United Kingdom)

^c KAROLINSKA INSTITUTE   (Sweden)

^d NATIONAL INSTITUTE ON AGING   (United States)

^e UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E; ASPARTATE AMINOTRANSFERASE; BIOLOGICAL MARKER; CHROMOGRANIN A; FATTY ACID BINDING PROTEIN; GELATINASE A; INTERLEUKIN 6 RECEPTOR; MONOCYTE CHEMOTACTIC PROTEIN 1; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); PEPTIDE FRAGMENT; PHOSPHOPROTEIN; PROTEIN CEREBROSPINAL FLUID LEVEL; TAU PROTEIN;

AGED; ALZHEIMER DISEASE; APOLIPOPROTEIN E GENE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BRAIN ATROPHY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE COURSE; DNA POLYMORPHISM; FEMALE; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; PREDICTION; PROTEIN CEREBROSPINAL FLUID LEVEL; ATROPHY; BRAIN; CEREBROSPINAL FLUID; COGNITION; COGNITIVE DEFECT; GENETICS; METABOLISM; MIDDLE AGED; NEUROIMAGING; PATHOLOGY; PATHOPHYSIOLOGY; PROGNOSIS; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; APOLIPOPROTEINS E; ATROPHY; BIOMARKERS; BRAIN; CEREBROSPINAL FLUID PROTEINS; COGNITION; COGNITIVE DYSFUNCTION; DISEASE PROGRESSION; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; NEUROIMAGING; PEPTIDE FRAGMENTS; PHOSPHOPROTEINS; PROGNOSIS; TAU PROTEINS;

EID: 84942645695     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0134368     Document Type: Article

References (51)

1. Jack CR, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol. 2010; 9: 119-28. PMID: 20083042
2. Villemagne VL, Burnham S, Bourgeat P, Brown B, Ellis K a, Salvado O, et al. Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. Lancet Neurol. 2013; 12: 357-67. PMID: 23477989
3. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. Springer; 1991; 82: 239-259.
4. Jack CR, Wiste HJ, Weigand SD, Rocca WA, Knopman DS, Mielke MM, et al. Age-specific population frequencies of cerebral β-amyloidosis and neurodegeneration among people with normal cognitive function aged 50-89 years: a cross-sectional study. Lancet Neurol. 2014; 13: 997-1005. PMID: 25201514
5. Fox NC, Warrington EK, Freeborough PA, Hartikainen P, Kennedy AM, Stevens JM, et al. Presymptomatic hippocampal atrophy in Alzheimer's disease. A longitudinal MRI study. Brain. OXFORD UNIV PRESS; 1996; 119: 2001-2007.
6. Desikan RS, Cabral HJ, Hess CP, Dillon WP, Glastonbury CM, Weiner MW, et al. Automated MRI measures identify individuals with mild cognitive impairment and Alzheimer's disease. Brain. Oxford University Press; 2009; 132: 2048-2057.
7. Blennow K, Hampel H. CSF markers for incipient Alzheimer's disease. Lancet. 2003; 2: 605-613. PMID: 14505582
8. Shaw LM, Korecka M, Clark CM, Lee VM-Y, Trojanowski JQ. Biomarkers of neurodegeneration for diagnosis and monitoring therapeutics. Nat Rev Drug Discov. 2007; 6: 295-303. PMID: 17347655
9. Davatzikos C, Bhatt P, Shaw LM, Batmanghelich KN, Trojanowski JQ. Prediction of MCI to AD conversion, via MRI, CSF biomarkers, and pattern classification. Neurobiol Aging. Elsevier Inc.; 2010;
10. Westman E, Muehlboeck J-S, Simmons A. Combining MRI and CSF measures for classification of Alzheimer's disease and prediction of mild cognitive impairment conversion. Neuroimage. Elsevier B.V.; 2012; 62: 229-38.
11. Mattsson N, Zetterberg H, Hansson O, Andreasen N, Parnetti L, Jonsson M, et al. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA. 2009; 302: 385-93. doi: 10.1001/jama.2009.1064 PMID: 19622817
12. Fagan AM, Perrin RJ. Upcoming candidate cerebrospinal fluid biomarkers of Alzheimer's disease. Biomark Med. 2012; 6: 455-476. doi: 10.2217/bmm.12.42 PMID: 22917147
13. Guerreiro R, Wojtas A, Bras J, Carrasquillo M, Rogaeva E, Majounie E, et al. TREM2 variants in Alzheimer's disease. N Engl J Med. 2013; 368: 117-27. doi: 10.1056/NEJMoa1211851 PMID: 23150934
14. Zhang J, Goodlett DR, Peskind ER, Quinn JF, Zhou Y, Wang Q, et al. Quantitative proteomic analysis of age-related changes in human cerebrospinal fluid. Neurobiol Aging. 2005; 26: 207-27. PMID: 15582749
15. Hu WT, Chen-Plotkin A, Arnold SE, Grossman M, Clark CM, Shaw LM, et al. Novel CSF biomarkers for Alzheimer's disease and mild cognitive impairment. Acta Neuropathol. 2010; 119: 669-78. doi: 10.1007/s00401-010-0667-0 PMID: 20232070
16. Craig-Schapiro R, Perrin RJ, Roe CM, Xiong C, Carter D, Cairns NJ, et al. YKL-40: a novel prognostic fluid biomarker for preclinical Alzheimer's disease. Biol Psychiatry. Elsevier Inc.; 2010; 68: 903-12.
17. Weiner MW, Aisen PS, Jack CR, Jagust WJ, Trojanowski JQ, Shaw L, et al. The Alzheimer's disease neuroimaging initiative: progress report and future plans. Alzheimers Dement. Elsevier Ltd; 2010; 6: 202-11.
18. Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen PS, Petersen RC, et al. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol. 2009; 65: 403-413. doi: 10.1002/ana.21610 PMID: 19296504
19. Shaw LM, Vanderstichele H, Knapik-Czajka M, Figurski M, Coart E, Blennow K, et al. Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI. Acta Neuropathol. 2011; 121: 597-609. doi: 10.1007/s00401-011-0808-0 PMID: 21311900
20. Trojanowski JQ, Vandeerstichele H, Korecka M, Clark CM, Aisen PS, Petersen RC, et al. Update on the biomarker core of the Alzheimer's Disease Neuroimaging Initiative subjects. Alzheimer's Dement. Elsevier Ltd; 2010; 6: 230-238.
21. Craig-Schapiro R, Kuhn M, Xiong C, Pickering EH, Liu J, Misko TP, et al. Multiplexed immunoassay panel identifies novel CSF biomarkers for Alzheimer's disease diagnosis and prognosis. PLoS One. 2011; 6: e18850. doi: 10.1371/journal.pone.0018850 PMID: 21526197
22. Hu WT, Holtzman DM, Fagan AM, Shaw LM, Perrin R, Arnold SE, et al. Plasma multianalyte profiling in mild cognitive impairment and Alzheimer disease. Neurology. 2012; 79: 897-905. PMID: 22855860
23. ADNI cerebrospinal fliud aliquot inventory description report [Internet]. Available: ADNI-CSF-Aliquot-Inventory-Description-v08-16-12.pdf
24. ADNI clinical procedures manual [Internet]. Dec. 10.1093/infdis/jis910
25. ADNI: Alzheimer's Disease Neuroimaging Initiative [Internet]. Available: http://www.adni-info.org/Scientists/ADNIStudyProcedures.aspx
26. Jack CR, Bernstein MA, Fox NC, Thompson P, Alexander G, Harvey D, et al. The Alzheimer's disease neuroimaging initiative (ADNI): MRI methods. J Magn Reson Imaging. Wiley Online Library; 2008; 27: 685-691.
27. Simmons A, Westman E, Muehlboeck S, Mecocci P, Vellas B, Tsolaki M, et al. MRI measures of Alzheimer's disease and the AddNeuroMed study. Ann N Y Acad Sci. 2009; 1180: 47-55.
28. Simmons A, Westman E, Muehlboeck S, Mecocci P, Vellas B, Tsolaki M, et al. The AddNeuroMed framework for multi-centre MRI assessment of Alzheimer's disease: experience from the first 24 months. Int J Geriatr Psychiatry. 2011; 26: 75-82. doi: 10.1002/gps.2491 PMID: 21157852
29. Westman E, Simmons A, Zhang Y, Muehlboeck J-S, Tunnard C, Liu Y, et al. Multivariate analysis of MRI data for Alzheimer's disease, mild cognitive impairment and healthy controls. Neuroimage. Elsevier Inc.; 2011; 54: 1178-87.
30. Westman E, Simmons A, Muehlboeck J-S, Mecocci P, Vellas B, Tsolaki M, et al. AddNeuroMed and ADNI: similar patterns of Alzheimer's atrophy and automated MRI classification accuracy in Europe and North America. Neuroimage. Elsevier Inc.; 2011; 58: 818-28.
31. Westman E, Aguilar C, Muehlboeck J-S, Simmons A. Regional magnetic resonance imaging measures for multivariate analysis in Alzheimer's disease and mild cognitive impairment. Brain Topogr. 2013; 26: 9-23. doi: 10.1007/s10548-012-0246-x PMID: 22890700
32. Fan Y, Batmanghelich N, Clark CM, Davatzikos C. Spatial patterns of brain atrophy in MCI patients, identified via high-dimensional pattern classification, predict subsequent cognitive decline. Neuroimage. 2008; 39: 1731-1743. PMID: 18053747
33. Davatzikos C, Xu F, An Y, Fan Y, Resnick SM. Longitudinal progression of Alzheimer's-like patterns of atrophy in normal older adults: the SPARE-AD index. Brain. 2009; 132: 2026-35. doi: 10.1093/brain/awp091 PMID: 19416949
34. Chang C, Lin C-J. LIBSVM: A Library for Support Vector Machines. ACM Trans Intell Syst Technol. 2011; 2: 1-27.
35. Hsu C, Chang C, Lin C. A Practical Guide to Support Vector Classification. Bioinformatics. Citeseer; 2010; 1: 1-16.
36. Zhang D, Wang Y, Zhou L, Yuan H, Shen D. Multimodal classification of Alzheimer's disease and mild cognitive impairment. Neuroimage. Elsevier Inc.; 2011; 55: 856-867.
37. Schölkopf B, Smola AJ. Learning with Kernels. Dietterich T, editor. Kybernetik. MIT Press; 2002.
38. Aguilar C, Westman E, Muehlboeck J-S, Mecocci P, Vellas B, Tsolaki M, et al. Different multivariate techniques for automated classification of MRI data in Alzheimer's disease and mild cognitive impairment. Psychiatry Res. Elsevier; 2013; 212: 89-98.
39. Mattsson N, Insel P, Nosheny R, Trojanowski JQ, Shaw LM, Jack CR, et al. Effects of cerebrospinal fluid proteins on brain atrophy rates in cognitively healthy older adults. Neurobiol Aging. Elsevier Ltd; 2014; 35: 614-22.
40. Blennow K, Davidsson P, Wallin A, Ekman R. Chromogranin A in cerebrospinal fluid: a biochemical marker for synaptic degeneration in Alzheimer's disease? Dementia. 1995; 6: 306-311. PMID: 8563783
41. Chiasserini D, Parnetti L, Andreasson U, Zetterberg H, Giannandrea D, Calabresi P, et al. CSF levels of heart fatty acid binding protein are altered during early phases of Alzheimer's disease. J Alzheimers Dis. 2010; 22: 1281-8. doi: 10.3233/JAD-2010-101293 PMID: 20930282
42. Olsson B, Hertze J, Ohlsson M, Nägga K, Höglund K, Basun H, et al. Cerebrospinal fluid levels of heart fatty acid binding protein are elevated prodromally in Alzheimer's disease and vascular dementia. J Alzheimers Dis. 2013; 34: 673-9. doi: 10.3233/JAD-121384 PMID: 23254629
43. Taylor DL, Diemel LT, Cuzner ML, Pocock JM. Activation of group II metabotropic glutamate receptors underlies microglial reactivity and neurotoxicity following stimulation with chromogranin A, a peptide up-regulated in Alzheimer's disease. J Neurochem. 2002; 82: 1179-1191. PMID: 12358765
44. Mattsson N, Insel P, Nosheny R, Zetterberg H, Trojanowski JQ, Shaw LM, et al. CSF protein biomarkers predicting longitudinal reduction of CSF β-amyloid42 in cognitively healthy elders. Transl Psychiatry. 2013; 3: e293. doi: 10.1038/tp.2013.69 PMID: 23962923
45. Soares HD, Potter WZ, Pickering E, Kuhn M, Immermann FW, Shera DM, et al. Plasma Biomarkers Associated With the Apolipoprotein E Genotype and Alzheimer Disease. Arch Neurol. 2012; 1-8.
46. Perrin RJ, Craig-Schapiro R, Malone JP, Shah AR, Gilmore P, Davis AE, et al. Identification and validation of novel cerebrospinal fluid biomarkers for staging early Alzheimer's disease. PLoS One. 2011; 6: e16032. doi: 10.1371/journal.pone.0016032 PMID: 21264269
47. Paterson RW, Bartlett JW, Blennow K, Fox NC, Shaw LM, Trojanowski JQ, et al. Cerebrospinal fluid markers including trefoil factor 3 are associated with neurodegeneration in amyloid-positive individuals. Transl Psychiatry. Nature Publishing Group; 2014; 4: 419.
48. Vemuri P, Wiste HJ, Weigand SD, Shaw LM, Trojanowski JQ, Weiner MW, et al. MRI and CSF biomarkers in normal, MCI, and AD subjects: predicting future clinical change. Neurology. 28 Jul 2009 73: 294-301. doi: 10.1212/WNL.0b013e3181af79fb PMID: 19636049
49. Apostolova LG, Hwang KS, Andrawis JP, Green AE, Babakchanian S, Morra JH, et al. 3D PIB and CSF biomarker associations with hippocampal atrophy in ADNI subjects. Neurobiol Aging. Elsevier Inc.; 2010; 31: 1284-1303.
50. Cui Y, Liu B, Luo S, Zhen X, Fan M, Liu T, et al. Identification of Conversion from Mild Cognitive Impairment to Alzheimer's Disease Using Multivariate Predictors. PLoS One. Public Library of Science; 2011; 6: e21896.
51. Misra C, Fan Y, Davatzikos C. Baseline and longitudinal patterns of brain atrophy in MCI patients, and their use in prediction of short-term conversion to AD: results from ADNI. Neuroimage. Elsevier Inc.; 2009; 44: 1415-22.